390 related articles for article (PubMed ID: 28923105)
1. Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma.
Kremer V; Ligtenberg MA; Zendehdel R; Seitz C; Duivenvoorden A; Wennerberg E; Colón E; Scherman-Plogell AH; Lundqvist A
J Immunother Cancer; 2017 Sep; 5(1):73. PubMed ID: 28923105
[TBL] [Abstract][Full Text] [Related]
2. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma.
Liu G; Rui W; Zheng H; Huang D; Yu F; Zhang Y; Dong J; Zhao X; Lin X
Eur J Immunol; 2020 May; 50(5):712-724. PubMed ID: 31981231
[TBL] [Abstract][Full Text] [Related]
3. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2.
Kershaw MH; Wang G; Westwood JA; Pachynski RK; Tiffany HL; Marincola FM; Wang E; Young HA; Murphy PM; Hwu P
Hum Gene Ther; 2002 Nov; 13(16):1971-80. PubMed ID: 12427307
[TBL] [Abstract][Full Text] [Related]
4. Engineering NK-92 Cell by Upregulating CXCR2 and IL-2 Via CRISPR-Cas9 Improves Its Antitumor Effects as Cellular Immunotherapy for Human Colon Cancer.
Gao L; Yang L; Zhang S; Ge Z; Su M; Shi Y; Wang X; Huang C
J Interferon Cytokine Res; 2021 Dec; 41(12):450-460. PubMed ID: 34935484
[TBL] [Abstract][Full Text] [Related]
5. Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α.
Najjar YG; Rayman P; Jia X; Pavicic PG; Rini BI; Tannenbaum C; Ko J; Haywood S; Cohen P; Hamilton T; Diaz-Montero CM; Finke J
Clin Cancer Res; 2017 May; 23(9):2346-2355. PubMed ID: 27799249
[No Abstract] [Full Text] [Related]
6. CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-β.
Jablonska J; Wu CF; Andzinski L; Leschner S; Weiss S
Int J Cancer; 2014 Mar; 134(6):1346-58. PubMed ID: 24154944
[TBL] [Abstract][Full Text] [Related]
7. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo.
Wennerberg E; Kremer V; Childs R; Lundqvist A
Cancer Immunol Immunother; 2015 Feb; 64(2):225-35. PubMed ID: 25344904
[TBL] [Abstract][Full Text] [Related]
8. TNF-α augments CXCR2 and CXCR3 to promote progression of renal cell carcinoma.
Sun KH; Sun GH; Wu YC; Ko BJ; Hsu HT; Wu ST
J Cell Mol Med; 2016 Nov; 20(11):2020-2028. PubMed ID: 27297979
[TBL] [Abstract][Full Text] [Related]
9. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma.
Mestas J; Burdick MD; Reckamp K; Pantuck A; Figlin RA; Strieter RM
J Immunol; 2005 Oct; 175(8):5351-7. PubMed ID: 16210641
[TBL] [Abstract][Full Text] [Related]
10. A C-X-C Chemokine Receptor Type 2-Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis.
Zhou Z; Xia G; Xiang Z; Liu M; Wei Z; Yan J; Chen W; Zhu J; Awasthi N; Sun X; Fung KM; He Y; Li M; Zhang C
Clin Cancer Res; 2019 Jun; 25(11):3317-3328. PubMed ID: 30796034
[TBL] [Abstract][Full Text] [Related]
11. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses.
Peng W; Ye Y; Rabinovich BA; Liu C; Lou Y; Zhang M; Whittington M; Yang Y; Overwijk WW; Lizée G; Hwu P
Clin Cancer Res; 2010 Nov; 16(22):5458-68. PubMed ID: 20889916
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 promotes CXCR2 to augment the stem-like property of renal cell carcinoma.
Huang CS; Tang SJ; Lee MH; Chang Wang CC; Sun GH; Sun KH
J Cell Mol Med; 2018 Dec; 22(12):5909-5918. PubMed ID: 30246456
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma.
Zhang Q; Xu J; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Wang Z; Fu Q; Zheng J
Oncol Rep; 2018 Dec; 40(6):3714-3724. PubMed ID: 30272343
[TBL] [Abstract][Full Text] [Related]
14. Human Brain Endothelial CXCR2 is Inflammation-Inducible and Mediates CXCL5- and CXCL8-Triggered Paraendothelial Barrier Breakdown.
Haarmann A; Schuhmann MK; Silwedel C; Monoranu CM; Stoll G; Buttmann M
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30704100
[TBL] [Abstract][Full Text] [Related]
15. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil transintestinal epithelial migration to CXCR2 ligands is regulated by adenosine.
Stadnyk AW; Carrigan SO; Otley AR
J Pediatr Gastroenterol Nutr; 2012 Mar; 54(3):414-21. PubMed ID: 21857250
[TBL] [Abstract][Full Text] [Related]
17. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling.
Zhou SL; Zhou ZJ; Hu ZQ; Li X; Huang XW; Wang Z; Fan J; Dai Z; Zhou J
Cancer Lett; 2015 Mar; 358(2):124-135. PubMed ID: 25462858
[TBL] [Abstract][Full Text] [Related]
18. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.
Polimeno M; Napolitano M; Costantini S; Portella L; Esposito A; Capone F; Guerriero E; Trotta A; Zanotta S; Pucci L; Longo N; Perdonà S; Pignata S; Castello G; Scala S
BJU Int; 2013 Sep; 112(5):686-96. PubMed ID: 23495770
[TBL] [Abstract][Full Text] [Related]
19. Differential usage of the CXC chemokine receptors 1 and 2 by interleukin-8, granulocyte chemotactic protein-2 and epithelial-cell-derived neutrophil attractant-78.
Wuyts A; Proost P; Lenaerts JP; Ben-Baruch A; Van Damme J; Wang JM
Eur J Biochem; 1998 Jul; 255(1):67-73. PubMed ID: 9692902
[TBL] [Abstract][Full Text] [Related]
20. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
